- Q1 2024 Bioatla Inc Earnings Call TranscriptMay 14, 2024$2.61 (-1.14%)Earnings
- Q4 2023 Bioatla Inc Earnings Call TranscriptMar 26, 2024$3.01 (+29.18%)Earnings
- Bioatla Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Bioatla Inc R&D Day TranscriptDec 13, 2023
- Q3 2023 Bioatla Inc Earnings Call TranscriptNov 07, 2023$1.76 (-4.35%)Earnings
- Bioatla Inc at HC Wainwright Investment Conference - New York(Pre Recorded) TranscriptSep 11, 2023
- Bioatla Inc at HC Wainwright Immune Cell Engager Virtual Conference TranscriptAug 17, 2023
- Q2 2023 Bioatla Inc Earnings Call TranscriptAug 01, 2023$2.88 (-3.68%)Earnings
- Bioatla Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Bioatla Inc at JMP Securities Life Sciences Conference TranscriptMay 15, 2023
- Q1 2023 Bioatla Inc Earnings Call TranscriptMay 11, 2023$3.21 (-3.02%)Earnings
- Q4 2022 Bioatla Inc Earnings Call TranscriptMar 23, 2023$2.3 (-1.71%)Earnings
- Q3 2022 Bioatla Inc Earnings Call TranscriptNov 03, 2022$6.36 (-1.40%)Earnings
- Q2 2022 Bioatla Inc Earnings Call TranscriptAug 09, 2022$3.61 (-3.48%)Earnings
- Q1 2022 Bioatla Inc Earnings Call TranscriptMay 04, 2022$4.08 (+6.53%)Earnings
Bioatla Inc at Jefferies Healthcare Conference Transcript
Well, thank you, everyone, for coming. I think we look forward to sharing with you a bit today about BioAtla. And I just want to start off before we get into any of the questions and so forth and just mention that the company is headquartered in San Diego, California. It was founded in 2007.
And what's really unique about the company is its CAB technology, conditionally active biologics. These are antibody-based therapeutics that are reversible and only have an ability to bind to target if it's on a cancer cell. If that same target happens to be on a normal cell, they won't touch it. And this is very different than the past where you often will have to take a cancer therapeutic, and it's a race between whether it kills the cancer or does harm to the individual on its normal -- on their normal cells.
So having a technology that's very specific and targeted to a cancer cell is not dependent on what is already existing on that cell is fundamental. And it's a technology that was pioneered at BioAtla, and we have over 700 patents,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)